Chen Y, et al. - The efficacy and safety of saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin ± metformin were evaluated in this prospective, multicentre, phase 3 study. Without increasing hypoglycaemia risk, add-on saxagliptin 5 mg once daily significantly improved glycaemic control in Chinese patients with type 2 diabetes inadequately controlled by insulin (± metformin). In addition, it was well tolerated in these patients.